Search Results - "Coenen, Juleon"

A randomised phase II trial of docetaxel versus docetaxel plus carboplatin in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial by Bouman-Wammes, Esther W., van den Berg, H. Pieter, de Munck, Linda, Beeker, Aart, Smorenburg, Carolien H., Vervenne, Walter L., Coenen, Juleon L.L.M., Verheul, Henk M.W., Gerritsen, Winald R., Van den Eertwegh, Alfons J.M.

“…Docetaxel is standard first-line chemotherapy for patients with metastatic castration–resistant prostate carcinoma (mCRPC). Docetaxel re-challenge has never…”
Get full text

Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial by de Jonge, Nick A, Sikkens, Jonne J, Zweegman, Sonja, Beeker, Aart, Ypma, Paula, Herbers, Alexandra H, Vasmel, Wies, de Kreuk, Arne, Coenen, Juleon L L M, Lissenberg-Witte, Birgit, Kramer, Mark H H, van Agtmael, Michiel A, Janssen, Jeroen J W M

“…Early antibiotic discontinuation has been advocated in haematology patients with fever of unknown origin during chemotherapy-induced neutropenia, but its…”
Get full text

Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study by Nielsen, Lene Kongsgaard, Stege, Claudia, Lissenberg-Witte, Birgit, van der Holt, Bronno, Mellqvist, Ulf-Henrik, Salomo, Morten, Bos, Gerard, Levin, Mark-David, Visser-Wisselaar, Heleen, Hansson, Markus, van der Velden, Annette, Deenik, Wendy, Coenen, Juleon, Hinge, Maja, Klein, Saskia, Tanis, Bea, Szatkowski, Damian, Brouwer, Rolf, Westerman, Matthijs, Leys, Rineke, Sinnige, Harm, Haukås, Einar, van der Hem, Klaas, Durian, Marc, Gimsing, Peter, van de Donk, Niels, Sonneveld, Pieter, Waage, Anders, Abildgaard, Niels, Zweegman, Sonja

“…Data on the impact of long term treatment with immunomodulatory drugs (IMiD) on health-related quality of life (HRQoL) is limited. The HOVON-87/NMSG18 study…”
Get full text

High-Intensity Care in the End-of-Life Phase of Castration-Resistant Prostate Cancer Patients: Results from the Dutch CAPRI-Registry by Westgeest, Hans M, Kuppen, Malou C P, van den Eertwegh, Fons A J M, van Oort, Inge M, Coenen, Juleon L L M, van Moorselaar, Jeroen R J A, Aben, Katja K H, Bergman, Andre M, Huinink, Daan Ten Bokkel, van den Bosch, Joan, Hendriks, Mathijs P, Lampe, Menuhin I, Lavalaye, Jules, Mehra, Niven, Smilde, Tineke J, Somford, Rik D M, Tick, Lidwine, Weijl, Nir I, van de Wouw, Yes A J, Gerritsen, Winald R, Groot, Carin A Uyl-de

“…Intensive end-of-life care (i.e., the overuse of treatments and hospital resources in the last months of life), is undesirable since it has a minimal clinical…”
Get more information

Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands by Westgeest, Hans M., Kuppen, Malou C.P., van den Eertwegh, Alphonsus J.M., de Wit, Ronald, Coenen, Juleon L.L.M., van den Berg, H.P. (Pieter), Mehra, Niven, van Oort, Inge M., Fossion, Laurent M.C.L., Hendriks, Mathijs P., Bloemendal, Haiko J., van de Luijtgaarden, Addy C.M., ten Bokkel Huinink, Daan, van den Bergh, A.C.M. (Fons), van den Bosch, Joan, Polee, Marco B., Weijl, Nir, Bergman, Andre M., Uyl-de Groot, Carin A., Gerritsen, Winald R.

“…Cabazitaxel has been shown to improve overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients after docetaxel in the TROPIC…”
Get full text

Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry by Kuppen, Malou C.P., Westgeest, Hans M., van den Eertwegh, Alphonsus J.M., van Moorselaar, Reindert J.A., van Oort, Inge M., Coenen, Juleon L.L.M., van den Bergh, A.C.M. (Fons), Mehra, Niven, Somford, Diederik M., Bergman, Andre M., ten Bokkel Huinink, Daan, Fossion, Laurent, Geenen, Maud M., Hendriks, Mathijs P., van de Luijtgaarden, Addy C.M., Polee, Marco B., Weijl, Nir I., van de Wouw, Agnes J., de Wit, Ronald, Uyl-de Groot, Carin A., Gerritsen, Winald R.

“…Cross resistance between androgen-receptor targeting therapies (ARTs) (abiraterone acetate plus prednisone [ABI+P] or enzalutamide [ENZ]) for treatment of…”
Get full text

Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma by Zweegman, Sonja, van der Holt, Bronno, Mellqvist, Ulf-Henrik, Salomo, Morten, Bos, Gerard M.J., Levin, Mark-David, Visser-Wisselaar, Heleen, Hansson, Markus, van der Velden, Annette W.G., Deenik, Wendy, Gruber, Astrid, Coenen, Juleon L.L.M., Plesner, Torben, Klein, Saskia K., Tanis, Bea C., Szatkowski, Damian L., Brouwer, Rolf E., Westerman, Matthijs, Leys, M.(Rineke) B.L., Sinnige, Harm A.M., Haukås, Einar, van der Hem, Klaas G., Durian, Marc F., Mattijssen, E.(Vera)J.M., van de Donk, Niels W.C.J., Stevens-Kroef, Marian J.P.L., Sonneveld, Pieter, Waage, Anders

“…The combination of melphalan, prednisone, and thalidomide (MPT) is considered standard therapy for newly diagnosed patients with multiple myeloma who are…”
Get full text

199. Short versus Extended Antibiotic Treatment with a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients with Fever of Unknown Origin: A Randomized Multicenter Noninferiority Trial by de Jonge, Nick A, Sikkens, Jonne, Zweegman, Sonja, Beeker, Aart, Ypma, Paula, Herbers, Alexandra, Vasmel, Wies, de Kreuk, Arne, Coenen, Juleon, Lissenberg-Witte, Birgit, Budding, Andries, Kramer, Mark, Van Agtmael, Michiel, Janssen, Jeroen

“…Abstract Background In hematology patients with high risk neutropenia due to intensive chemotherapy the optimal antibiotic treatment duration for fever of…”
Get full text

Randomized Phase III Trial in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma Comparing Melphalan-Prednisone-Thalidomide Followed By Thalidomide Maintenance (MPT-T) Versus Melphalan-Prednisone-Lenalidomide Followed By Maintenance with Lenalidomide (MPR-R); A Joint Study of the Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) and the Nordic Myeloma Study Group (NMSG) by Zweegman, Sonja, Holt, Bronno van der, Mellqvist, Ulf-Henrik, Salomo, Morten, Bos, Gerard M.J., Levin, Mark-David, Visser-Wisselaar, Heleen A, Hansson, Markus, van der Velden, Annette WG, Deenik, Wendy, Gruber, Astrid, Coenen, Juleon LLM, Plesner, Torben, Klein, Saskia K, Tanis, Bea, Szatkowski, Damian L, Brouwer, Rolf, Westerman, Matthijs, Leys, M (Rineke) BL, van de Donk, Niels W.C.J., Haukås, Einar, van der Hem, Klaas, Durian, MF, Mattijssen, E (Vera) JM, Sinnige, Harm AM, Stevens-Kroef, Marian JPL, Sonneveld, Pieter, Waage, Anders

“…▪ Background Melphalan-based regimens, combined with Prednisone and Thalidomide (THAL)(MPT) or Bortezomib (V)(MPV), have been approved as standard therapy of…”
Get full text